Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray
Status:
Completed
Trial end date:
2017-06-30
Target enrollment:
Participant gender:
Summary
Non-controlled pilot study. Two groups: Group A: naloxone nasal spray max 8 mg/per day; Group
B: naloxone max 16 mg/per day. Study duration 8 weeks. Brief intervention.
Phase:
Phase 2
Details
Lead Sponsor:
Finnish Institute for Health and Welfare National Institute for Health and Welfare, Finland